Investigational drug · Phase 2
RVU120
Also called: SEL120
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "RVU120"
First trial start
2024
Jan 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RVU120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Acute Myeloid Leukaemia (AML)
- High-risk Myelodysplastic Syndrome
- Low Risk Myelodysplastic Syndromes
- Acute Myeloid Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Oncology · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "RVU120" as an intervention, largest first.
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRecruiting
Ryvu Therapeutics SAIndustry
NCT06191263 · 98 participants (planned) · Start Jan 5, 2024 · Primary completion Aug 2027
Drug: RVU120; Venetoclax · For: Acute Myeloid Leukemia
Sites: Grenoble, France; Le Mans, France; Lille, France · 37 sites in all
Ryvu Therapeutics SAIndustry
NCT05052255 · 66 participants · Start Aug 13, 2021 · Primary completion Oct 2, 2025
Drug: RVU120 · For: Advanced Solid Tumor
Sites: Bielsko-Biala, Poland; Gdansk, Poland; Katowice, Poland · 7 sites in all
Ryvu Therapeutics SAIndustry
NCT06268574 · 62 participants · Start Jan 23, 2024 · Primary completion Jun 30, 2025
Drug: RVU120 · For: Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome
Sites: La Tronche, France; Le Mans, France; Lille, France · 41 sites in all
Ryvu Therapeutics SAIndustry
NCT04021368 · 51 participants · Start Sep 4, 2019 · Primary completion May 21, 2024
Drug: RVU120(SEL120) · For: Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome
Sites: Miami, Florida; Atlanta, Georgia; St Louis, Missouri · 10 sites in all
- Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaNot yet recruiting
Bożenna Dembowska BagińskaAcademic, hospital or other
NCT07865130 · 48 participants (planned) · Start Sep 2026 · Primary completion Jun 2033
Drug: RVU120; Everolimus (Afinitor) tablets · For: Medulloblastoma Recurrent; Medulloblastoma
Sites: Warsaw, Poland
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsActive, not recruiting
GCP-Service International West GmbHIndustry
NCT06243458 · 41 participants · Start Sep 10, 2024 · Primary completion May 2026
Drug: RVU120 (SEL120) · For: Low Risk Myelodysplastic Syndromes
Sites: Grenoble, France; Nice, France; Paris, France · 25 sites in all
Ryvu Therapeutics SAIndustry
NCT06397313 · 36 participants · Start Sep 19, 2024 · Primary completion Jun 30, 2026
Drug: RVU120; Ruxolitinib · For: Myelofibrosis
Sites: Bologna, Italy; Brescia, Italy; Catania, Italy · 18 sites in all
- RVU120 Rollover StudyEnrolling by invitation
Ryvu Therapeutics SAIndustry
NCT06987058 · 14 participants (planned) · Start Dec 4, 2025 · Primary completion Dec 2026
Drug: RVU120; Ruxolitinib · For: Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome
Sites: Nice, France; Pessac, France; Chorzów, Poland · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML.
Statkiewicz M, Rumienczyk I, Pakulska U, et al. · Cells 2026
- Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy.
Pakulska U, Obacz M, Woźnicki J, et al. · bioRxiv 2026
- Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19.
Hatcher JM, Vatsan PS, Wang E, et al. · ACS Med Chem Lett 2021
- SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T, Mikula M, Żykiewicz E, et al. · Oncotarget 2017
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.